We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
DOVPRELA Viatris Pty Ltd
Product name
DOVPRELA
Sponsor
Accepted date
Feb-2026
Active ingredients
pretomanid
Summary of proposed indication
DOVPRELA (pretomanid), in combination with bedaquiline, linezolid and moxifloxacin is proposed for the treatment of adults with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to rifampicin, with or without resistance to isoniazid.
DOVPRELA, in combination with bedaquiline and linezolid, is proposed for the treatment of adults with pulmonary TB due to M. tuberculosis resistant to rifampicin and a fluoroquinolone with or without resistance to isoniazid.
DOVPRELA, in combination with bedaquiline and linezolid, is proposed for the treatment of adults with pulmonary TB due to M. tuberculosis resistant to rifampicin and a fluoroquinolone with or without resistance to isoniazid.
Application type
A (new medicine)
Publication date
Feb-2026